Abstract
Immunoglobulins (Ig) of pooled healthy human sera were purified by affinity chromatography based on their reactivity with human IgG. This Ig fraction represent connected, natural antibodies (NAbs) and here are denoted as anti- IgG antibodies. The data revealed that IgG, IgA and IgM isotypes are constituents of anti-IgG fraction. The ability of anti- IgG antibodies to prevent infection of PBMC by HIV-1 was demonstrated. They exhibited different neutralizing activity depending on the phenotype of the tested virus. The efficacy of neutralization was comparable to monoclonal antibodies (MAbs) IgG1b12 at least for the HIV-1 92HT593B strain. These studies suggest that connected antibodies thus, constituents of immune network, could prevent infection by HIV-1. NAbs as essential components of therapeutic molecules of intravenous Ig (IVIg) have a beneficial effect on variety of immunological disorders by affecting the structure, function and dynamics of the immune network. Since, hallmark of HIV-1 infection are immunological disorders we hypothesizes that they might be corrected to some extend by anti-IgG antibodies.
Keywords: Natural autoantibodies, immune network, neutralization of HIV-1
Current HIV Research
Title: Anti-IgG Antibodies from Sera of Healthy Individuals Neutralize HIV-1 Primary Isolates.
Volume: 5 Issue: 2
Author(s): Radmila Metlas, Tanja Srdic and Veljko Veljkovic
Affiliation:
Keywords: Natural autoantibodies, immune network, neutralization of HIV-1
Abstract: Immunoglobulins (Ig) of pooled healthy human sera were purified by affinity chromatography based on their reactivity with human IgG. This Ig fraction represent connected, natural antibodies (NAbs) and here are denoted as anti- IgG antibodies. The data revealed that IgG, IgA and IgM isotypes are constituents of anti-IgG fraction. The ability of anti- IgG antibodies to prevent infection of PBMC by HIV-1 was demonstrated. They exhibited different neutralizing activity depending on the phenotype of the tested virus. The efficacy of neutralization was comparable to monoclonal antibodies (MAbs) IgG1b12 at least for the HIV-1 92HT593B strain. These studies suggest that connected antibodies thus, constituents of immune network, could prevent infection by HIV-1. NAbs as essential components of therapeutic molecules of intravenous Ig (IVIg) have a beneficial effect on variety of immunological disorders by affecting the structure, function and dynamics of the immune network. Since, hallmark of HIV-1 infection are immunological disorders we hypothesizes that they might be corrected to some extend by anti-IgG antibodies.
Export Options
About this article
Cite this article as:
Metlas Radmila, Srdic Tanja and Veljkovic Veljko, Anti-IgG Antibodies from Sera of Healthy Individuals Neutralize HIV-1 Primary Isolates., Current HIV Research 2007; 5 (2) . https://dx.doi.org/10.2174/157016207780077093
DOI https://dx.doi.org/10.2174/157016207780077093 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Use of the Zebrafish Model to Aid in Drug Discovery and Target Validation
Current Topics in Medicinal Chemistry Editorial [Hot Topic: Spinal Cord Injury and Repair - Part I (Executive Editor: Weihong Pan)]
Current Pharmaceutical Design Calcium-Independent Membrane Damage by Venom Phospholipases A2
Protein & Peptide Letters Mitocans: Mitochondrial Targeted Anti-Cancer Drugs as Improved Therapies and Related Patent Documents
Recent Patents on Anti-Cancer Drug Discovery Convection Enhanced Delivery of Macromolecules for Brain Tumors
Current Drug Discovery Technologies The Physiology of Learning and Memory: Role of Peptides and Stress
Current Protein & Peptide Science Inflammation as a Therapeutic Target in Acute Ischemic Stroke Treatment
Current Topics in Medicinal Chemistry Peptide-based Vaccines in the Treatment of Specific Allergy
Current Drug Targets - Inflammation & Allergy Mast Cells: Target and Source of Neuropeptides
Current Pharmaceutical Design Antioxidant Effects of Coumarins Include Direct Radical Scavenging, Metal Chelation and Inhibition of ROS-Producing Enzymes
Current Topics in Medicinal Chemistry Elastic Liposomes for Topical and Transdermal Drug Delivery
Current Drug Delivery Targeting Tumor Immunosuppressive Microenvironment for the Prevention of Hepatic Cancer: Applications of Traditional Chinese Medicines in Targeted Delivery
Current Topics in Medicinal Chemistry A Novel Method for Screening of Anti-Cancer Drugs: Availability of Screening in Acidic Medium
Recent Patents on Biomedical Engineering (Discontinued) A New Application Route of Nitrofurantoin: Preparation and Characterization of Novel Transdermal Formulations
Current Drug Delivery Beyond Bile Acids: Targeting Farnesoid X Receptor (FXR) with Natural and Synthetic Ligands
Current Topics in Medicinal Chemistry Sirtuins and Resveratrol-Derived Compounds: A Model for Understanding the Beneficial Effects of the Mediterranean Diet
Endocrine, Metabolic & Immune Disorders - Drug Targets Blood Stem Cells and non-Hematological Clinical Practice: Pragmatics Before Therapeutics
Current Pharmaceutical Biotechnology Dysfunction of Glutamate Receptors in Microglia May Cause Neurodegeneration
Current Alzheimer Research Angiotensin-Converting Enzyme Inhibitors: Mechanisms of Action and Implications In Anesthesia Practice
Current Pharmaceutical Design Recent Androgen Receptor Antagonists in Prostate Cancer
Mini-Reviews in Medicinal Chemistry